Coeptis Therapeutics Holdings (Coeptis Therapeutics Holdings) GF Value Rank : 0 (As of May. 28, 2024)

View and export this data going back to 2022. Start your Free Trial

What is Coeptis Therapeutics Holdings GF Value Rank?

Coeptis Therapeutics Holdings has the GF Value Rank of 0.

The GF Value Rank is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Coeptis Therapeutics Holdings GF Value Rank Related Terms

Thank you for viewing the detailed overview of Coeptis Therapeutics Holdings's GF Value Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Coeptis Therapeutics Holdings (Coeptis Therapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Coeptis Therapeutics Holdings Inc (NAS:COEP) » Definitions » GF Value Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

105 Bradford Road, Suite 420, Wexford, PA, USA, 15090

Website

https://www.coeptistx.com

Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio comprises multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.

Executives

Tara Desilva	director	105 BRADFORD RD., SUITE 420, WEXFORD PA 15090
David Mehalick	director, 10 percent owner, officer: CEO and President	5000 TRESSDALE DRIVE, GIBSONIA PA 15044
Christopher P. Cochran	director	105 BRADFORD RD., SUITE 420, WEXFORD PA 15090
Gene Salkind	director	1165 WRACK ROAD, MEADOWBROOK PA 19046
Daniel Alexander Yerace	director, officer: VP of Operations	402 SCHOMBURG COURT, CRANBERRY TOWNSHIP PA 16066
Chris Calise	director, 10 percent owner, officer: Chief Financial Officer	801 S. POINTE DRIVE SUITE TH-1, MIAMI BEACH FL 33139
Philippe Deschamps	director	105 BRADFORD RD, SUITE 420, WEXFORD PA 15090
Christine Elise Sheehy	officer: CFO and Secretary	206 TAMARACK DRIVE, MARS PA 16046
Harraden Circle Investments, Llc	10 percent owner	299 PARK AVE, 21ST FLOOR, NEW YORK NY 10171
Harraden Circle Investors Gp, Lp	10 percent owner	299 PARK AVE., 21ST FLOOR, NEW YORK NY 10171
Harraden Circle Investors Gp, Llc	10 percent owner	299 PARK AVE., 21ST FLOOR, NEW YORK NY 10171
Fortmiller Frederick Vincent Jr.	10 percent owner	151 LULL ROAD, NEW BOSTON NH 03070
Harraden Circle Investors, Lp	10 percent owner	299 PARK AVENUE, 21ST FLOOR, NEW YORK NY 10171
Plc Barclays	10 percent owner	1 CHURCHILL PLACE, CANARY WHARF, LONDON X0 E14 5HP
Paul J Glazer	10 percent owner	250 WEST 55TH ST, SUITE 30A, NEW YORK NY 10019